PerTe: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer patients—Efficacy and safety of pertuzumab in “real life" setting.

作者
Daniela Cianniello,Antonella Prudente,Roberta Caputo,Michela Piezzo,Maria Riemma,Beatrice Savastano,Stefania Cocco,Ivana Cerillo,Rossella Lauria,Mario Giuliano,Cinzia Cardalesi,Giuseppe Buono,Grazia Arpino,Giovanni Iodice,Francesca Di Rella,Carmen Pacilio,Salvatore Del Prete,Sabino De Placido,Michelino De Laurentiis
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (15_suppl): e12654-e12654
标识
DOI:10.1200/jco.2018.36.15_suppl.e12654
摘要

e12654 Background: Standard preoperative systemic therapy for HER2+ breast cancer (BC) patients (pts) includes chemotherapy (CT) and Trastuzumab (T). Two randomized phase II trials, NeoSphere and TRYPHAENA, showed that the addition of Pertuzumab (P) to a T–based neoadjuvant therapy improves the pathologic complete response (pCR) rate, with no evidence that P increased the rate of cardiac dysfunction. Based on these two trials, on June 2015, European Medicine Agency (EMA) approved dual HER2 blockade with T+P for the neoadjuvant treatment of HER2+ BC. PerTe is an observational study, aimed to evaluate the efficacy and safety of P+T as neoadjuvant treatment of HER2+ BC in a real practice setting. Methods: 65 pts treated with P+T+CT as neoadjuvant therapy were identified by 3 Italian Institutions since July 2015. Based on clinical practice of belonging institution, pts were treated with 3 different CT regimens: 1) ECx4 followed by P+T+weekly paclitaxel for 12, 2) ECx4 followed by P+T+docetaxel for 4 cycles and 3) P+T+docetaxel for 6 cycles. The primary objective is to evaluate the pCR rate, defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. The secondary objective is to evaluate the safety profile of dual HER2 blockade. Results: To date, 48 pts completed the study treatment and underwent surgery, 2 experienced disease progression at the end of neoadjuvant treatment, while 16 pts are still on treatment. Of all evaluable pts, 28 (56%) had a HER2+, Luminal B, ductal infiltrating carcinoma (DCI) and 22 (44%) had a HER2+, Hormone Receptor-negative (HR-) DCI. pCR was achieved in 36 (72%) pts, 12 pts (24%) had residual disease at histologic examination. The highest pCR rate was observed in pts with high level of ki-67 and HR- (86%). No difference was observed among treatment regimens. No significant cardiac toxicity was detected. Conclusions: Neoadjuvant treatment with P+T+CT in a real practice setting is highly effective and does not raise cardiac safety concerns, regardless of the chemotherapy regimen used. We are going to involve more institutions in order to collect a larger sample.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爆米花的应助被苦柒采纳,获得10
1秒前
2秒前
可爱的函函的应助被Nowaki采纳,获得10
2秒前
含蓄乐菱关注了科研通微信公众号
2秒前
3秒前
跳舞的麦麦完成签到,获得积分10
3秒前
4秒前
Evander完成签到,获得积分10
4秒前
小马甲的应助被科研通管家采纳,获得10
4秒前
YW完成签到,获得积分10
5秒前
5秒前
科研通AI2S的应助被科研通管家采纳,获得10
5秒前
5秒前
伊啊亚完成签到,获得积分10
5秒前
Hello的应助被科研通管家采纳,获得10
5秒前
斯文若血发布了新的文献求助10
5秒前
null的应助被AURORA采纳,获得10
6秒前
FashionBoy的应助被科研通管家采纳,获得10
7秒前
田様的应助被不舍天真采纳,获得10
7秒前
香蕉觅云的应助被科研通管家采纳,获得10
7秒前
7秒前
华仔的应助被科研通管家采纳,获得10
7秒前
molihuakai的应助被科研通管家采纳,获得10
7秒前
7秒前
wanci的应助被科研通管家采纳,获得30
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
Ava的应助被科研通管家采纳,获得10
8秒前
8秒前
Orange的应助被科研通管家采纳,获得10
8秒前
8秒前
烟花的应助被科研通管家采纳,获得10
8秒前
8秒前
我是老大的应助被科研通管家采纳,获得10
8秒前
科研小牛完成签到,获得积分10
8秒前
evildoer发布了新的文献求助10
8秒前
儒雅的蓝天完成签到,获得积分10
9秒前
10秒前
11秒前
11秒前
爆米花的应助被xm采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008